MAP2K7 and melanoma: Many studies underline the potential role of target therapy, especially MEK inhibitors, to mediate immunostimulatory or immunosuppressive effects..[9] In accordance with our data, short course of MEK and BRAF inhibitors improve efficacy of immunotherapy in melanoma.[10]